Skip to main
AGEN
AGEN logo

Agenus (AGEN) Stock Forecast & Price Target

Agenus (AGEN) Analyst Ratings

Based on 2 analyst ratings
Buy
Strong Buy 50%
Buy 0%
Hold 50%
Sell 0%
Strong Sell 0%

Bulls say

Agenus Inc possesses a strong clinical pipeline focused on cancer therapies, which is bolstered by proprietary products such as botensilimab (AGEN1811) and balstilimab, targeting mechanisms for immune activation. The potential for additional revenue generation through compassionate use programs for these therapies is promising, as it not only provides funding but also aids in gathering real-world clinical data to reinforce their efficacy. Furthermore, encouraging preliminary regulatory sentiment regarding bot/bal in the context of metastatic microsatellite-stable colorectal cancer (MSS-CRC) and efficacy seen in triple-negative breast cancer (TNBC) and ER+ breast cancer enhances the company's value proposition and growth prospects.

Bears say

Agenus Inc faces significant risks that could adversely impact its stock performance, primarily stemming from potential safety signals in its clinical programs and the possibility of lower-than-expected efficacy in its studies. The company may also encounter heightened commercial competition in the oncology space, alongside regulatory concerns that could affect the progression of its therapies. Additionally, financing requirements and challenges regarding intellectual property protection further contribute to a negative outlook for the company's financial stability and growth prospects.

Agenus (AGEN) has been analyzed by 2 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 0% recommend Buy, 50% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Agenus and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Agenus (AGEN) Forecast

Analysts have given Agenus (AGEN) a Buy based on their latest research and market trends.

According to 2 analysts, Agenus (AGEN) has a Buy consensus rating as of Nov 26, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $14.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $14.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Agenus (AGEN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.